FOXO1 (Forkhead box O1)

Pediatric maxillofacial RMS represents a distinct subgroup with a prognosis intermediate to that of other head and neck subsites. Outcomes are heavily influenced by early chemotherapy response, as well as tumor biology.

FOXO1 carries both prognostic and predictive relevance in mRCC and independently predicts greater benefit from IO+TKI therapy. Integration of FOXO1 with complementary immune gene features into an RF-based model provides a promising framework for precision immunotherapy in advanced RCC.

Mechanistically, VIP-mediated autophagy was associated with sirtuin 3 (SIRT3) downregulation and increased Ac-FOXO1 levels, with SIRT3 overexpression effectively counteracting the VIP-induced autophagic effects. Our findings demonstrate that VIP induces both cytotoxic effects and autophagy in VPAC1-expressing RCC cells through modulation of the SIRT3/FOXO1 signaling pathway, highlighting its potential therapeutic value for renal cell carcinoma.

We demonstrate marked tumor growth inhibition in all FP-RMS PDXs treated with single agent FGF401 (FGFR4-specific inhibitor) and single agent lenvatinib (multi-kinase FGFR-inhibitor), and report a clinical response to lenvatinib in a relapsed metastatic FP-RMS patient. Altogether, we identified new sarcoma patients who may benefit from FGFR-inhibitors, most notably FP-rhabdomyosarcoma via FGFR4/FGF8 co-expression.

Elevated levels of IGF-1 expression were observed, while FOXO1 expression was decreased. These findings indicate that early maternal probiotic supplementation improves lymphocyte activity and facilitates the remodeling of the splenic immune system in offspring and thus represents an innovative approach to immune programming during early life.

P3, N=342, Not yet recruiting, Children's Oncology Group

In summary, breast masses in adolescent and middle-aged women comprised of small round cell tumor cells with an invasive growth pattern should prompt consideration of metastatic ARMS as a diagnostic possibility. Accurate diagnosis requires a careful integration of medical history, morphologic and immunophenotypic tumoral features, and confirmation through the detection of specific alterations in the FOXO1 gene.

The intersection between ChIP-Seq data and RNA sequencing data showed an overall of 12 lncRNAs that were differentially expressed upon FOXO1 knockdown and also have a FOXO1 binding site in their promoter region, namely ZFAS1, LINC00862, SNHG32, LINC01962, SNHG12, 1QCH-AS1, LINC00324, DCXR-DT, GLUD1P2, FAB5P3, JPX, and SMPD4BP. In conclusion, 12 lncRNAs were identified as potential downstream targets of FOXO1, suggesting that those lncRNAs could mediate FOXO1 functions in HCC.

Partially overlapping gene signatures are activated by PAX3/7::FOXO1 in vivoModified MNase ChIP reveals PAX3/7::FOXO1 bind nucleosomal and subnucleosomal DNAPAX7::FOXO1 binds degenerate paired/homeobox motifs within nucleosome targetsEach fusion engages distinct nucleosomal gene targets.

Our findings indicate that periplogenin suppresses hepatocarcinogenesis by inducing cellular senescence through activation of the FOXO1/P53 pathway. These results highlight the potential of periplogenin as a novel therapeutic agent for the treatment of hepatocellular carcinoma.

This review highlights a need for further research of the TME in each fusion subtype. This will improve our understanding of how the fusion gene drives malignancy and ultimately aids in the development of novel treatment strategies.

Their structures were elucidated using 1D and 2D NMR experiments and their absolute configurations determined using semisynthetic and electronic circular dichroism methods. The gonystylones were found to be cytotoxic to rhabdomyosarcoma cells at low micromolar concentrations (3-19 μM).